Who Pulled the Plug on Hope for an Alzheimer’s Treatment?

Hope springs eternal… But does it really today in this age of personal and professional second-guessing and gotcha? If we wait for perfection, is there hope? Wrote Alexander Pope, in the 1700s, considered among the foremost English poets in the 18th century: “Hope springs eternal in the human breast; Man never Is, but always To be blest. The soul, uneasy, and confin'd from home, Rests and expatiates in a life to come.” — An Essay On Man Pope, sadly, may not have been a poet before his time, but of his time. Time understandably changes perspectives—from the pure hope of

New Perspectives: A 14-Year-Old’s Advocacy on Alzheimer’s

My name is Sohta Cheung-Naito, and I am a rising ninth-grader living in Westchester, New York who is committed to advocating for families touched by Alzheimer’s disease.

My Story: What Congress Can Do to Support Brain Health Equity for Patients & Caregivers

My mother’s journey with Alzheimer’s disease over the past six years exemplifies the challenges facing people living with the disease, their caregivers and communities of color.

UsAgainstAlzheimer’s Data Brief Drawing New Attention to Brain Health Equity for Communities of Color

A new data brief from the UsAgainstAlzheimer’s Center for Brain Health Equity highlighted the 41 congressional districts associated with the top 25 counties that have the highest prevalence of Alzheimer’s among Black and Latino Americans in the Medicare program has drawn new attention to the social determinants of health present in the districts and counties most impacted by Alzheimer’s among people of color. During a virtual briefing to launch the data brief, leaders in Congress and at the Centers for Disease Control and Prevention (CDC) cited the need to promote early detection and diagnosis, support people living with the disease

UsA2’s 2020 Annual Report Chronicles a Decade of Impact

In the 10 years since we founded UsAgainstAlzheimer’s, we have seen enormous progress in the fight to stop Alzheimer’s disease. Our 2020 Annual Report features milestones from this past year as well as highlights from a decade of impact. Last month, after our Annual Report was completed, the Food and Drug Administration (FDA) approved the first disease-modifying therapy and the first-ever therapy approved for mild cognitive impairment. This approval of Aduhelm is a true breakthrough moment in Alzheimer’s history, providing patients, for the first time, the chance to consider a therapy that slows the progression of their Alzheimer’s disease. While